Daily cardiology

Dual RAAS inhibition in the treatment of systolic heart failure; at a glance Part two: Eplerenone in the guidelines 25.01.2022 9:13 ↓

Latest guideline recommendations on the use of RAAS inhibitors in heart failure patients

Cardiopoint (12): Two-Drug Combinations as First-Step Antihypertensive treatment 25.01.2022 19:40 ↓

Initial administration of two-drug combinations in HTN

HeartCast 1: practical approach to the treatment of HFrEF 25.01.2022 10:06 ↓

The first HeartCast: HFrEF management

Self-measured blood pressure monitoring at home 25.01.2022 15:58 ↓

What to teach the patients about recording their blood pressure themselves

CardioPoint (10): The growing burden of cardiovascular diseases 25.01.2022 12:08 ↓

Emphasizing the importance of CVD prevention and management

What is new in the 2020 ESC Guideline for the diagnosis and management of Atrial Fibrillation 25.01.2022 13:05 ↓

Part Four: LSM, bleeding management, pregnancy, POAF, sex related differences

CardioPoint (11): Antithrombotic therapy in patients with AF treated with OAC undergoing PCI 25.01.2022 11:00 ↓

Quick Review of ACC 2020 Expert Consensus Pathway of Antithrombotic Management

What is new in the 2020 ESC Guideline for the diagnosis and management of AF 25.01.2022 22:02 ↓

Part Three: Cardioversion, rhythm control, catheter ablation Long term anti arrhythmic drugs

Cardiopoint (13): Management of stage 1 hypertension in adults with low cardiovascular risk 25.01.2022 9:29 ↓

Stage 1 HTN in low risk patients

Dual RAAS inhibition in the treatment of systolic heart failure; at a glance Part one: Eplerenone in the pipeline 25.01.2022 9:22 ↓

Latest pieces of evidence regarding the use of RAAS inhibitors in heart failure patients

Apixaban Hub (4) 25.01.2022 15:18 ↓

NOAC Choice

CardioPoint (1): Statins-Who is eligible?-Which dose? 18.01.2022 4:32 ↓

A Brief Description on Practical Points in Cardiometabolic Field

Guideline Made Easy (5) 18.01.2022 4:31 ↓

Practical Guide for treatment of high blood cholesterol Part Two

CardioPoint (3): NOACs in Elderly 18.01.2022 6:35 ↓

A Brief Description on Practical Points in Anticoagulation

CardioPoint (2): NOAC Monitoring, Do NOACs Need Monitoring? 18.01.2022 4:50 ↓

A Brief Description on Practical Points in Anticoagulation

PCSK9 Inhibition from bench to bedside (4) 17.01.2022 12:18 ↓

Part Four: The Lower, The Better

PCSK9 Inhibition from bench to bedside (1) 17.01.2022 10:44 ↓

Part One: A success story

CardioPoint (6): Treatment Target & Goal for LDL-Cholesterol 17.01.2022 7:42 ↓

A Brief Description on Practical Points in Cardiometabolic Field

Guideline Made Easy (1) 17.01.2022 9:22 ↓

Practical Guide for Treatment of High Blood Pressure (Part One)

Apixaban Hub (1) 17.01.2022 17:42 ↓

When to use, when not to use & which dose?

Guideline Made Easy (4) 17.01.2022 5:17 ↓

Practical Guide for treatment of high blood cholesterol Part One

At a glance: ACEI and ARB in COVID-19 Era 17.01.2022 8:12 ↓

The challenge of to use or not to use ACEI/ARBs in patients with COVID-19

Apixaban Hub (2) 17.01.2022 15:34 ↓

Apixaban in the pipeline: landmark clinical trials

At a glance; How dual pathway found its way into ESC guidelines? 17.01.2022 8:26 ↓

Rivaroxaban on board for CCS

What is new in the 2020 ESC Guideline for the diagnosis and management of AF 17.01.2022 15:02 ↓

Updated changes in AF ESC 2020 compared to previous Guidelines (Part one)